Drug intelligence / Profile preview

isoflurane + vecuronium

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Inhalation, Intravenous
01

Overview

Isoflurane + vecuronium is a combination of two pharmaceutical agents commonly used together during general anesthesia for surgical procedures. Isoflurane is a volatile inhalational anesthetic that induces and maintains general anesthesia by enhancing inhibitory neurotransmission, primarily through potentiation of GABA receptor activity and modulation of other ion channels, leading to central nervous system depression, muscle relaxation, and loss of consciousness. Vecuronium is a non-depolarizing neuromuscular blocking agent (aminosteroid class) that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, resulting in skeletal muscle paralysis. When used together, isoflurane can potentiate the neuromuscular blockade produced by vecuronium; this allows for lower doses of vecuronium to achieve the desired level of muscle relaxation during surgery[1][2][5]. The combination does not have unique brand or code names but represents standard clinical practice in anesthesiology.

02

Targets

Nicotinic Acetylcholine ReceptorGABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on isoflurane + vecuronium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoflurane + vecuronium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call